Abstract 351P
Background
Aortic stenosis is the most common valvular complication of mediastinal radiotherapy. In 2016 was shown that not only radiotherapy but chemotherapy with anthracyclines alone may provoke the development of valvular heart diseases (VHD). But there are still not clear time frames of VHD development.
Methods
We present a single-center retrospective analysis of a cohort with breast cancer history who were treated in cardiology departments. Total 91 patients were included in this study. ECHO data and time till first symptoms and surgical treatment were assessed in all patients.
Results
Different VHD were revealed in 48.35% (n=44) of patients. Among them 54.5% (n=24) had aortic stenosis, 34.1% (n=15) – mitral regurgitation, 4.5% (n=2) – mitral stenosis with regurgitation, 2.3% (n=1) – isolated aortic regurgitation and the same number of isolated mitral stenosis. During 15 months 25 patients were undergoing surgical treatment. In 2 of them VHD was first diagnosed before cancer treatment, so they weren’t included in the subsequent analysis. The oncological age in operated patients was 60 [42; 68] years. The time till first signs of VHD was 8 [4; 16.5] years. In all patients dyspnea was presented, 39% of patients had angina and only in 21.7% had presyncopes and syncopes. The median time from oncological age till surgery was 11 [7; 22] years. We also revealed correlation between oncological age and time till first VHD signs and surgical treatment (r = -0.76 and r = -0.71 respectively).
Conclusions
Given the widespread prevalence of degenerative aortic stenosis in older age patients, it is advisable to assess valves condition not only before radiation and chemotherapy but also recommend more frequent echocardiographic monitoring after, as well as use of new visualization techniques, such as CT (calcium score) and 18F-NaF PET-CT (as marker of calcification).
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
183P - Textbook outcome as a measure of surgical quality assessment and prognosis in gastric neuroendocrine carcinoma: A large multicenter sample analysis
Presenter: You-Xin Gao
Session: e-Poster Display Session
184P - Development and external validation of a nomogram to predict recurrence-free survival after R0 resection for stage II/III gastric adenocarcinoma: An international multicenter study
Presenter: Bin-Bin Xu
Session: e-Poster Display Session
185P - Effect of sarcopenia on short- and long-term outcomes of patients with gastric neuroendocrine tumour after radical surgery: Results from a large, two-institutional series
Presenter: Ling-Qian Wang
Session: e-Poster Display Session
186P - Characterization of the gastroenteropancreatic neuroendocrine tumour patient journey
Presenter: George Fisher Jr
Session: e-Poster Display Session
187P - More is not always better: A multicenter study in lymphadenectomy during gastrectomy for gastric neuroendocrine carcinoma
Presenter: Qi-Yue Chen
Session: e-Poster Display Session
188P - The impact of sarcopenia on chemotherapy toxicity and survival rate among pancreatic cancer patients who underwent chemotherapy: A systematic review and meta-analysis
Presenter: Billy Susanto
Session: e-Poster Display Session
189P - Prognostic value of inflammation-based score for patients treated with FOLFIRINOX (FFX) or gemcitabine plus nab-paclitaxel (GnP)
Presenter: Takahiro Yamamura
Session: e-Poster Display Session
190P - Outcomes from the Asian region of the phase III APACT trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) alone for patients (pts) with resected pancreatic cancer (PC)
Presenter: Joon Oh Park
Session: e-Poster Display Session
191P - First-line liposomal irinotecan + 5 fluorouracil/leucovorin + oxaliplatin in patients with pancreatic ductal adenocarcinoma: Results from a phase I/II study
Presenter: Andrew Dean
Session: e-Poster Display Session
192P - A multicenter crossover analysis of first and second-line FOLFIRINOX or gemcitabine plus nab-paclitaxel administered to pancreatic cancer patients: Results from the NAPOLEON study
Presenter: Kenta Nio
Session: e-Poster Display Session